Friday, 22 Mar 2019

You are here

Plaquenil During Lupus Pregnancy Lessens Flares

A large cohort study of pregnant and non-pregnant women with systemic lupus erythematosus has shown that lupus flares are increased during pregnancy and in the 3  months follwing delivery.

Investigators studied 1349 patients in the Hopkins Lupus Cohort between 14–45 years of age. They assessed disease activity an its relationship to pregnancy, postpartum or non-pregnant/non-postpartum periods. Among the 1349 patients, there were 398 pregnancies in 304 patients.

They found a 59% increased rate of lupus flare (defined by global assessment) during pregnancy (HR: 1.59). 

The use of hydroxychloroquine (HCQ) during pregnancy influenced these outomces (compared with non-pregnant/non-postpartum periods):

  • More Flares without HCQ use (HR 1.83; 95% CI 1.34 to 2.45) and
  • Less Flares with HCQ use (HR 1.26; 95% CI 0.88 to 1.69) 

This study shows that HCQ during pregnancy lessens the risk of flare during and after pregnancy.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Resistant Hypertension Common in SLE

Rates of resistant hypertension were doubled among patients with systemic lupus erythematosus (SLE), significantly increasing their mortality risks, a retrospective single-center study found.

Among patients with SLE, the prevalence of resistant hypertension was 10.2% compared with 5.3% among controls (OR 2.02, 95% CI 1.60-2.55, P<0.0001), according to Cecilia P. Chung, MD, and colleagues from Vanderbilt University in Nashville.

Improved Mortality Trends in Lupus Nephritis

The mortality rate from end- stage renal disease (ESRD) in lupus nephritis (LN) patients has significantly decreased in the last decade.

Cyclosporin and IVIG Effective in Kawasaki's Disease

A Lancet study has shown that adding cyclosporin to intravenous immunoglobulin (IVIG) Kawasaki disease patients, who were predicted to be resistant to IVIG, was both safe and effective in averting severe coronary artery outcomes.

Brazilian Guidelines for Systemic Autoimmune Myopathies

The Myopathy Committee of the Brazilian Society of Rheumatology (BSR) has put forward recommendations for the management of patients with systemic autoimmune myopathies (SAM).

The challenge has been that there is a paucity of effective controlled clinical trials, and hence, glucocorticoids (GC) have played a first-line and prominent role in the treatment of SAM.

EULAR Consensus Guidelines for Juvenile Localized Scleroderma

A EULAR international committee of 15 experts in pediatric rheumatology have established consensus-based recommendations for the management of juvenile localised scleroderma (JLS).

JLS is an uncommon disorder that is commonly seen by pediatric and adult rheumatologists. Evidence-based guidelines are sparse and management is mostly based on physicians’ experience.